Logo

BioTrove Inks Screening Deal with Blue Sky

Mar 24, 2006

NEW YORK, March 24 (GenomeWeb News) - BioTrove and Blue Sky will collaborate to create a screening portfolio for challenging drug targets, Biotrove said this week.

 

Under the agreement, BioTrove will use Blue Sky proteins as a component of an assay used by BioTrove's RapidFire platform to screen for biomarkers.

 

The collaboration will focus initially on targets in metabolic disorders and oncology, BioTrove said.

 

Financial details were not provided.

Breaking News
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.